J Flanagan1, P Kathryn Gray2, N Hahn3, J Hayes4, L J Myers5, C Carney-Doebbeling6, C J Sweeney7. 1. Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis; Kansas City Cancer Center, US Oncology, Kansas City. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston. 3. Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis. 4. Department of Medicine, Dana Farber Cancer Institute, Boston. 5. Division of General Internal Medicine and Geriatrics, Department of Medicine, Indiana University School of Medicine, Indianapolis; Health Services Research and Development Center of Excellence on Implementing Evidence-Based Practice (CIEBP), Roudebush VA Medical Center, Indianapolis. 6. Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis; Regenstrief Institute Inc, Indianapolis, USA. 7. Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis; Department of Medicine, Dana Farber Cancer Institute, Boston. Electronic address: christopher_sweeney@dfci.harvard.edu.
Abstract
BACKGROUND: Metabolic syndrome (MS) is a set of risk factors that includes obesity and insulin resistance and has been implicated in the development of prostate cancer. Its impact on androgen deprivation therapy (ADT) efficacy has not been studied. PATIENTS AND METHODS: Retrospective study of prostate cancer patients seen from 1998 to 2005 in a medical oncology clinic. MS, as defined by modified Adult Treatment Panel III criteria, was assessed at the time of initiation of ADT. The study end points were time to prostate-specific antigen (PSA) progression and overall survival (OS) from time of starting ADT. RESULTS: Eighty-two patients treated with ADT and data to assess for presence of MS were identified. Median age in men with and without MS was 70 years and 49% of the patients evaluated met criteria for MS. Median time to PSA progression for patients with MS was 16 versus 36 months without MS (P=0.003). The median OS for patients with MS was 36.5 months after commencing ADT compared with 46.7 months for those patients without MS (P=0.061). CONCLUSIONS: This preliminary data suggest that MS is a risk factor for earlier development of castration-resistant prostate cancer and support the need for a prospective evaluation of this finding.
BACKGROUND:Metabolic syndrome (MS) is a set of risk factors that includes obesity and insulin resistance and has been implicated in the development of prostate cancer. Its impact on androgen deprivation therapy (ADT) efficacy has not been studied. PATIENTS AND METHODS: Retrospective study of prostate cancerpatients seen from 1998 to 2005 in a medical oncology clinic. MS, as defined by modified Adult Treatment Panel III criteria, was assessed at the time of initiation of ADT. The study end points were time to prostate-specific antigen (PSA) progression and overall survival (OS) from time of starting ADT. RESULTS: Eighty-two patients treated with ADT and data to assess for presence of MS were identified. Median age in men with and without MS was 70 years and 49% of the patients evaluated met criteria for MS. Median time to PSA progression for patients with MS was 16 versus 36 months without MS (P=0.003). The median OS for patients with MS was 36.5 months after commencing ADT compared with 46.7 months for those patients without MS (P=0.061). CONCLUSIONS: This preliminary data suggest that MS is a risk factor for earlier development of castration-resistant prostate cancer and support the need for a prospective evaluation of this finding.
Authors: Xiaoye Zhu; Peter C Albertsen; Gerald L Andriole; Monique J Roobol; Fritz H Schröder; Andrew J Vickers Journal: Eur Urol Date: 2011-11-24 Impact factor: 20.096
Authors: Jiun-Hung Geng; Anna Plym; Kathryn L Penney; Mark Pomerantz; Lorelei A Mucci; Adam S Kibel Journal: Prostate Cancer Prostatic Dis Date: 2022-01-24 Impact factor: 5.554
Authors: Xiaoye Zhu; Pim J van Leeuwen; Erik Holmberg; Meelan Bul; Sigrid Carlsson; Fritz H Schröder; Monique J Roobol; Jonas Hugosson Journal: J Med Screen Date: 2012-09 Impact factor: 2.136
Authors: Matteo Ferro; Daniela Terracciano; Carlo Buonerba; Giuseppe Lucarelli; Danilo Bottero; Sisto Perdonà; Riccardo Autorino; Alessandro Serino; Francesco Cantiello; Rocco Damiano; Iulia Andras; Sabino De Placido; Giuseppe Di Lorenzo; Michele Battaglia; Barbara A Jereczek-Fossa; Vincenzo Mirone; Ottavio De Cobelli Journal: Future Oncol Date: 2016-09-14 Impact factor: 3.404
Authors: Sarah M Rudman; Kathryn P Gray; Julie L Batista; Michael J Pitt; Edward L Giovannucci; Peter G Harper; Massimo Loda; Lorelei A Mucci; Christopher J Sweeney Journal: BJU Int Date: 2016-03-08 Impact factor: 5.588